Zhejiang Hisun Pharmaceutical (SHA:600267) and subsidiary Hanhui Pharmaceutical won pre-bids for five products under China's drug procurement program, according to a Tuesday filing with the Shanghai bourse.
Three of the drugs are antibiotic injections, including imipenem and cilastatin sodium, vancomycin hydrochloride, and teicoplanin.
Two other products, tacrolimus for injection and epirubicin hydrochloride, are chemotherapy drugs.